Biodexa Pharmaceuticals Plc
NASDAQ Capital MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Stephen Anthony Stamp
- Full Time Employees
- 11
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 1 Caspian Point Cardiff WA United Kingdom CF10 4DQ
- IPO Date
- Dec 7, 2015
- CIK
- 0001643918
- Website
- biodexapharma.com
- Similar Companies
- Business
- Biodexa Pharmaceuticals Plc is a clinical-stage biopharmaceutical company that develops innovative treatments targeting diseases with high unmet medical needs, including familial adenomatous polyposis (FAP), non-muscle invasive bladder cancer (NMIBC), type 1 diabetes (T1D), and rare or orphan brain cancers; its lead product candidates comprise eRapa (a proprietary oral tablet formulation of rapamycin, an mTOR inhibitor designed for improved bioavailability and consistent pharmacokinetics via nanotechnology and pH-sensitive polymers), tolimidone (an oral selective lyn kinase inhibitor demonstrating glycemic control through insulin sensitization in animal models), and MTX110 (a liquid formulation of panobinostat for convection-enhanced delivery directly to brain tumors, bypassing the blood-brain barrier). Founded in 2000 and headquartered in Cardiff, United Kingdom, the company operates primarily in the biotechnology research sector with approximately 21 full-time employees and maintains its registered office at 1 Caspian Point, Caspian Way, Cardiff CF10 4DQ. Biodexa lists on NASDAQ under the ticker BDRX and was formerly known as Midatech Pharma Plc, changing its name in March 2023; it pursues strategic collaborations, including with Janssen, Melior, and Emtora Biosciences, the latter securing a total of $20.0 million in non-dilutive grants from the Cancer Prevention & Research Institute of Texas to support the eRapa Phase 3 program in FAP. Recent developments include raising $7 million in gross proceeds from warrant exercises in May 2024 to fund initial eRapa Phase 3 commitments; enrolling the first patients in the U.S. for the pivotal Phase 3 Serenta trial in FAP in August 2025; receiving European Medicines Agency Clinical Trial Application approval in early November 2025; and activating the first European site at the University of Bonn, Germany, for active patient screening later that month, with initial sites planned across four European countries and first European patient enrollment expected in the fourth quarter of 2025.
Result of Annual General Meeting
Biodexa Announces Pricing of $3.5 Million Registered Direct Offering & Concurrent Private Placement of Pre-Funded Warrants and Warrants
Approval from Health Canada to expand Serenta Registrational Phase 3 trial in FAP and Update on Serenta Progress
Postponement and Re-scheduling of Annual General Meeting
Biodexa issues letter to Shareholders
Biodexa Announces Partnership with Syngene To Manufacture MTX240 GMP Clinical Trial Supplies
Preliminary Results for the Year Ended 31 December 2025
Biodexa Launches Global Early Access Program for eRapa for FAP Patients Through Strategic Partnership with Tanner Pharma Group
Biodexa Pharmaceuticals (NASDAQ:BDRX) Shares Scheduled to Reverse Split on Monday, April 6th
ADR Ratio Change
Financial Comparison: Biodexa Pharmaceuticals (NASDAQ:BDRX) versus Radiopharm Theranostics (NASDAQ:RADX)
Biodexa Announces Support for Life's a Polyp Foundation First U.S. Patient Advocacy Group for FAP Patients
Biodexa Licenses Phase 1 Ready Drug Candidate from Otsuka for Rare Stomach Cancer
Biodexa Announces Exclusive License of Otsuka's OPB-171775, a potent Phase 1 ready Molecular Glue for GIST
Biodexa Pharmaceuticals PLC Unsponsored ADR (NASDAQ:BDRX) Short Interest Update
Appointment of Fiona Sharp to the Board as Chief Financial Officer and Company Secretary
Cadrenal Therapeutics (NASDAQ:CVKD) & Biodexa Pharmaceuticals (NASDAQ:BDRX) Financial Analysis
Biodexa Announces Pricing of $10 Million Public Offering
Biodexa Announces Enrolment of First European Patients into Pivotal Phase 3 Serenta Trial in FAP
Biodexa Activates First European Site for Registrational Phase 3 Serenta Trial in FAP